What you'll learn in this expert session
The new vaccines for respiratory syncytial virus (RSV) are here, and patients are asking about them, courtesy of a far-reaching public awareness campaign about RSV. In this presentation, Prof Paul Griffin will provide a timely update on what treating health professionals need to know about these vaccines. This includes the current ATAGI recommendations on who should be vaccinated and when, their effectiveness, side effects, cost and the practical differences between Arexvy and Abrysvo; the two RSV vaccines currently available.
About the Expert
Prof Paul Griffin
An Infectious Diseases Physician and Clinical Microbiologist, Prof Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013, and most recently, to his conjoint role as Head of the Mater Clinical Unit for the University of Queensland School of Medicine.
Prof Griffin is an accomplished clinical trial investigator, having fulfilled the role of Principal Investigator in over 150 clinical trials, particularly in Infectious Diseases including 8 COVID-19 vaccines. Despite an already demanding role at the Mater, Prof Griffin continues as a member of the AMA Queensland Council 2023-2024, and as a board member and scientific advisory board member of the Immunisation Coalition, with active interest in vaccine education and advocacy, becoming a trusted media authority and spokesperson across the nation during the COVID-19 pandemic
Course curriculum
-
1
How to complete this course
-
Instructions
-
-
2
RSV Update
-
Summary
-
Video lecture (25 mins)
-
Quiz: test your learning (10 mins)
-
-
3
Document your CPD here
-
CPD Documentation and Reflection Activity Tool
-
-
4
Feedback
-
Please let us know your thoughts
-